Clinical Policy Bulletin: Ovarian Vein Embolization and Sclerotherapy for Pelvic Congestion Syndrome
Aetna considers ovarian vein embolization medically necessary for the treatment of pelvic congestion syndrome (PCS) when both of the following criteria are met:
The member has had a definitive diagnostic venography, CT or MRI; and
The member has failed a trial of appropriate pharmacotherapy (e.g., analgesics, hormonal therapy).
Aetna considers ovarian vein embolization for the treatment of PCS experimental and investigational when criteria are not met.
Aetna considers sclerotherapy in the treatment of pelvic congestion syndrome experimental and investigational because the clinical evidence is not sufficient to permit conclusions on the health outcome effects of sclerotherapy in the treatment of pelvic congestion syndrome.
Pelvic congestion syndrome (PCS, also known as pelvic venous incompetence [PVI]), a condition associated with ovarian vein incompetence, is manifested by pelvic pain of variable intensity, that is heightened before or during menses and that is aggravated by prolonged standing, fatigue and intercourse. Laparoscopic and venographic evidence of varicosities confirm the diagnosis of PCS. The traditional therapy for PCS includes both medical approaches (e.g., dihydroergotamine, ovarian suppression, and rheologic agents) and surgical approaches (e.g., hysterectomy, uterine ventro-suspension, ovarian vein ligation, and excision).
Ovarian vein embolization is a minimally invasive treatment alternative for PCS. The technique, usually performed by an interventional radiologist, involves threading a catheter, guided by X-ray imaging, through the groin to the ovarian veins. If the imaging reveals a cluster of serpentine veins, tiny stainless steel coils and/or absorbable sponges, or liquids such as glue are passed through the catheter into the ovarian vein, forming a clot that subsequently blocks the accumulation of blood in the varices. Careful selection of patients and use of appropriate angiographic and technical skills by the interventional radiologist are requisite for the success of this therapeutic alternative.
Chung and Huh (2003) assessed the effectiveness of various treatments for PCS in patients with different stress levels. These investigators analyzed 106 patients with PCS confirmed with laparoscopy and venography, who did not respond to medication after 4 to 6 months medication. They were divided into 3 groups: (i) embolotherapy; (ii) hysterectomy with bilateral oophorectomy and hormone replacement therapy; and (iii) hysterectomy with unilateral oophorectomy. The visual analog scale was used to measure degree of pain; stress level data were scored with the revised social readjustment rating scale. Embolotherapy was significantly more effective at reducing pelvic pain, compared to the other methods (p < 0.05). The mean percentage decrease in pain was significantly greater in the patients with lower stress scores (p < 0.05). The authors concluded that ovarian and/or internal iliac vein embolization appears to be a safe, well-tolerated, effective treatment for PCS that has not responded to medication.
Smith (2012) stated that PCS is one of many causes of chronic pelvic pain. It is generally accepted that this is attributable to ovarian and pelvic vein incompetence that may result in varices in the lower limb leading to presentation in varicose vein clinics. However, far more patients have pelvic varices associated with varicose veins in the lower limb than have PCS. Magnetic resonance imaging and computed tomographic venography are usually used in the diagnosis of this condition and criteria have been established to identify pelvic varices. Many different treatments have been used to manage the symptoms of pelvic congestion. Hysterectomy combined with oophrectomy, open surgical ligation of ovarian veins and laparoscopic vein ligation have been used in the past. The most common treatments used currently involve embolization of pelvic and ovarian veins. The results of this treatment have been published in a limited number of clinical series, usually with fairly short follow-up periods. These treatments may be complicated by migration of embolization of coils used to occlude veins. The longest duration of follow-up currently reported is 5 years. Limited clinical evidence supports the use of embolotherapy in the management of PCS.
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
Other HCPCS codes related to the CPB:
Injection, dihydroergotamine mesylate, per 1 mg
Injection, leuprolide acetate (for depot suspension), per 3.75 mg
Goserelin acetate implant, per 3.6 mg
Leuprolide acetate (for depot suspension), 7.5 mg
Leuprolide acetate implant, 65 mg
Injection, ganirelix acetate, 250 mcg
ICD-9 codes covered if selection criteria are met:
Pelvic congestion syndrome
CPT codes not covered if selection criteria are met:
ICD-9 codes not covered for indications listed in the CPB:
Pelvic congestion syndrome
The above policy is based on the following references:
Cordts PR, Eclavea A, Buckley PJ, et al. Pelvic congestion syndrome: Early clinical results after transcatheter ovarian vein embolization. J Vasc Surg. 1998;28(5):862-868.
Capasso P, Simons C, Trotteur G, et al. Treatment of symptomatic pelvic varices by ovarian vein embolization. Cardiovasc Interven Radiol. 1997;20(2):107-111.
Tarazov PG, Prozorovskij KV, Ryzhkov VK. Pelvic pain syndrome caused by ovarian varices. Treatment by transcatheter embolization. Acta Radiol. 1997;38(6):1023-1025.
Edwards RD, Robertson IR, MacLean AB, Hemingway AP. Case report: Pelvic pain syndrome - successful treatment of a case by ovarian vein embolization. Clin Radiol. 1993;47(6):429-431.
Ryder R. Chronic pelvic pain. Am Fam Physician. 1996;54(7):2225-2232, 2237.
Venbrux A, Lambert DL. Embolization of the ovarian veins as a treatment for patients with chronic pelvic pain caused by pelvic venous incompetence. Curr Opin Obstet Gynecol. 1999;11:395-399.
Belenky A, Bartal G, Atar E, et al. Ovarian varices in healthy female kidney donors: Incidence, morbidity, and clinical outcome. AJR Am J Roentgenol. 2002;179(3):625-627.
Venbrux AC, Chang AH, Kim HS, et al. Pelvic congestion syndrome (pelvic venous incompetence): Impact of ovarian and internal iliac vein embolotherapy on menstrual cycle and chronic pelvic pain. J Vasc Interv Radiol. 2002;13(2 Pt 1):171-178.
Pieri S, Agresti P, Morucci M, de' Medici L. Percutaneous treatment of pelvic congestion syndrome. Radiol Med (Torino). 2003;105(1-2):76-82.
Bachar GN, Belenky A, Greif F, Atar E, Gat Y, Itkin M, Verstanding A. Initial experience with ovarian vein embolization for the treatment of chronic pelvic pain syndrome. Isr Med Assoc J. 2003;5(12):843-846.
Chung MH, Huh CY. Comparison of treatments for pelvic congestion syndrome. Tohoku J Exp Med. 2003;201(3):131-138.
d'Archambeau O, Maes M, De Schepper AM. The pelvic congestion syndrome: Role of the 'nutcracker phenomenon' and results of endovascular treatment. JBR-BTR. 2004;87(1):1-8.
Hobbs JT. Varicose veins arising from the pelvis due to ovarian vein incompetence. Int J Clin Pract. 2005;59(10):1195-1203.
Kim HS, Malhotra AD, Rowe PC, et al. Embolotherapy for pelvic congestion syndrome: Long-term results. J Vasc Interv Radiol. 2006;17(2 Pt 1):289-297.
Liddle AD, Davies AH. Pelvic congestion syndrome: Chronic pelvic pain caused by ovarian and internal iliac varices. Phlebology. 2007;22(3):100-104.
Kwon SH, Oh JH, Ko KR, et al. Transcatheter ovarian vein embolization using coils for the treatment of pelvic congestion syndrome. Cardiovasc Intervent Radiol. 2007;30(4):655-661.
Creton D, Hennequin L, Kohler F, Allaert FA. Embolisation of symptomatic pelvic veins in women presenting with non-saphenous varicose veins of pelvic origin - three-year follow-up. Eur J Vasc Endovasc Surg. 2007;34(1):112-117.
Asciutto G, Asciutto KC, Mumme A, Geier B. Pelvic venous incompetence: Reflux patterns and treatment results. Eur J Vasc Endovasc Surg. 2009;38(3):381-386.
Tu FF, Hahn D, Steege JF. Pelvic congestion syndrome-associated pelvic pain: A systematic review of diagnosis and management. Obstet Gynecol Surv. 2010;65(5):332-340.
Smith PC. The outcome of treatment for pelvic congestion syndrome. Phlebology. 2012;27 Suppl 1:74-77.
Ball E, Khan KS, Meads C. Does pelvic venous congestion syndrome exist and can it be treated? Acta Obstet Gynecol Scand. 2012;91(5):525-528.
Katz MD, Sugay SB, Walker DK, et al. Beyond hemostasis: Spectrum of gynecologic and obstetric indications for transcatheter embolization. Radiographics. 2012;32(6):1713-1731.
Laborda A, Medrano J, de Blas I, et al. Endovascular treatment of pelvic congestion syndrome: Visual analog scale (VAS) long-term follow-up clinical evaluation in 202 patients. Cardiovasc Intervent Radiol. 2013;36(4):1006-1014.
Hocquelet A, Le Bras Y, Balian E, et al. Evaluation of the efficacy of endovascular treatment of pelvic congestion syndrome. Diagn Interv Imaging. 2014;95(3):301-306.
Nasser F, Cavalcante RN, Affonso BB, et al. Safety, efficacy, and prognostic factors in endovascular treatment of pelvic congestion syndrome. Int J Gynaecol Obstet. 2014;125(1):65-68.
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.